Novartis to Expand Generics Business - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Novartis to Expand Generics Business

Pharmaceutical Technology

Novartis to Expand Generics Hold


If all goes as planned for Novartis (Basel, Switzerland, www.novartis.com), it could soon become the world’s largest generic pharmaceuticals manufacturer. The company announced on Monday plans to buy Hexal (Munich, Germany) and Eon Labs (New York, NY). The $8.4-billion cash purchase, expected to close by the end of the year, would add more than 120 products, including antidepressants, painkillers, and cholesterol-reducing medicines, and a pipeline of new generic therapies of brand-name drugs set to lose their patents between 2005 and 2009. 

Coupled with Novartis’s existing drug unit, Sandoz, the new expansion is projected to bring more than $5 billion in sales and hold an estimated 10% of the $100-billion generics market by 2010. Generics reportedly already make up 50% of pharmaceutical sales volume in the United States.

Generic drugs would account for only 15% of Novartis’ sales after the acquisition, and analysts were quick to point out that the biggest risk in this expansion would be competition—a fact shown just two days after the announcement.

Just yesterday (February 23), the name of Novartis’ main competitor, Teva Pharmaceutical Industry (Netanya, Israel) came up when UK-based Shire Pharmaceuticals announced that it had received a Paragraph IV Notice letter from Teva. The notice advised of Teva’s filing of an abbreviated new drug application (ANDA) for its amphetamine combination product, which is a generic version of Shire’s attention deficit and hyperactivity disorder drug "ADDERALL XR." Teva joins a group of other generics makers such as Barr Laboratories and IMPAX Laboratories that also have filed ANDAs for their respective generic versions of ADDERALL XR.

Maribel Rios

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
FDASIA was signed into law two years ago. Where has the most progress been made in implementation?
Reducing drug shortages
Breakthrough designations
Protecting the supply chain
Expedited reviews of drug submissions
More stakeholder involvement
Reducing drug shortages
27%
Breakthrough designations
9%
Protecting the supply chain
41%
Expedited reviews of drug submissions
9%
More stakeholder involvement
14%
View Results
Jim Miller Outsourcing Outlook Jim Miller Health Systems Raise the Bar on Reimbursing New Drugs
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerThe Mainstreaming of Continuous Flow API Synthesis
Jill Wechsler Regulatory Watch Jill Wechsler Industry Seeks Clearer Standards for Track and Trace
Siegfried Schmitt Ask the Expert Siegfried SchmittData Integrity
Sandoz Wins Biosimilar Filing Race
NIH Translational Research Partnership Yields Promising Therapy
Clusters set to benefit from improved funding climate but IP rights are even more critical
Supplier Audit Program Marks Progress
FDA, Drug Companies Struggle with Compassionate Use Requests
Source: Pharmaceutical Technology,
Click here